EMA Recommends Granting a Marketing Authorisation for Aumolertinib By Ogkologos - January 8, 2026 144 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with EGFR-mutated NSCLC Source RELATED ARTICLESMORE FROM AUTHOR New Survey Highlights the Role of Clinical Practice Guidelines to Improve Care for Patients with Rare Cancers FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology MOST POPULAR Shelter Cat Who Battled Breast Cancer Seeks Fellow Survivor to Give... October 30, 2019 Preparing for the End of the U.S. Public Health Emergency (PHE):... February 13, 2023 PARP Inhibitors Show Promise as Initial Treatment for Ovarian Cancer October 29, 2019 Darolutamide Delays the Spread of Some Prostate Cancers March 15, 2019 Load more HOT NEWS When Prenatal DNA Tests Point to Cancer Educators Raise Money in Memory of Teacher Who Dedicated Herself to... Mom Battling Cancer Lets 4-Yr-Old Give Her “Best Haircut Ever.” Prostate cancer: Lessons Learned from My Breast Cancer
